Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003843 · ClinicalTrials.gov registry record
Irinotecan in Treating Patients With Colorectal Cancer
A clinical trial, sponsored by California Cancer Consortium.
- Terminated
- Registry status
- 28
- Enrollment target
NCT00003843 is a clinical trial that was terminated before completion, run by California Cancer Consortium. The registered enrollment target is 28 participants.
The verdict
NCT00003843 was terminated before completion, sponsored by California Cancer Consortium.
- TERMINATED
- Registry status
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have colorectal cancer.
Interventions
- GENETIC mutation analysis
- GENETIC polymorphism analysis
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 1998-10 |
| Est. Completion | 2001-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003843
The ClinicalTrials.gov registry entry for NCT00003843 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is California Cancer Consortium, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which mutation analysis is the first listed.
NCT00003843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003843 about?
NCT00003843 is a clinical study titled "Irinotecan in Treating Patients With Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have colorectal cancer.
What is the current status of trial NCT00003843?
This trial is currently terminated. The enrollment target is 28 participants. The study started on 1998-10. Estimated completion is 2001-02.
What interventions are being tested in trial NCT00003843?
The interventions under investigation include: mutation analysis (GENETIC), polymorphism analysis (GENETIC), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003843?
This trial is sponsored by California Cancer Consortium, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.